Seres therapeutics and nestlÉ health science announce u.s. commercial availability of vowst™, the first and only fda-approved microbiota-based oral therapeutic for prevention of recurrence of c. difficile infection

Cambridge, mass. & hoboken, n.j.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) and nestlÉ health science today announced that vowst™ (fecal microbiota spores, live-brpk) is now commercially available for patients. vowst, formerly called ser-109, is the first and only u.s. food and drug administration (fda)-approved orally administered microbiota-based therapeutic to prevent recurrence of c. difficile infection (cdi) in adults following antibacterial treatment for recurrent cdi (rcdi.
MCRB Ratings Summary
MCRB Quant Ranking